Tender detail
Non-exclusive rebate agreement for natalizumab infusion solution concentrate
Summary
DAK-Gesundheit intends to conclude non-exclusive rebate agreements with pharmaceutical companies for medicines containing natalizumab, limited to concentrate for solution for infusion (ATC L04AG03). The agreements run from 1 December 2026 to 30 November 2028, but end earlier if an exclusive agreement for the active ingredient takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.